Point mutations within the FLT3 tyrosine kinase domain (FLT3-TKDs), such as the most prevalent D835Y mutation, are found in 5–10% of patients with AML, whereas their significance on prognosis remains unclear. Here, FLT3 is linked to acute myeloid leukemia.